Dhawan Lab, Paediatric Liver GI and Nutrition Center and MowatLabs, Institute of Liver Studies, King's College London at King's College Hospital, London SE5 9PJ, UK.
Dhawan Lab, Paediatric Liver GI and Nutrition Center and MowatLabs, Institute of Liver Studies, King's College London at King's College Hospital, London SE5 9PJ, UK
Philos Trans R Soc Lond B Biol Sci. 2018 Jul 5;373(1750). doi: 10.1098/rstb.2017.0229.
Liver transplantation represents the standard treatment for people with an end-stage liver disease and some liver-based metabolic disorders; however, shortage of liver donor tissues limits its availability. Furthermore, whole liver replacement eliminates the possibility of using native liver as a possible target for future gene therapy in case of liver-based metabolic defects. Cell therapy has emerged as a potential alternative, as cells can provide the hepatic functions and engraft in the liver parenchyma. Various options have been proposed, including human or other species hepatocytes, hepatocyte-like cells derived from stem cells or more futuristic alternatives, such as combination therapies with different cell types, organoids and cell-biomaterial combinations. In this review, we aim to give an overview of the cell therapies developed so far, highlighting preclinical and/or clinical achievements as well as the limitations that need to be overcome to make them fully effective and safe for clinical applications.This article is part of the theme issue 'Designer human tissue: coming to a lab near you'.
肝移植是治疗终末期肝病和一些基于肝脏的代谢紊乱患者的标准疗法;然而,肝供体组织的短缺限制了其应用。此外,整个肝脏的替换消除了在基于肝脏的代谢缺陷的情况下,将天然肝脏作为未来基因治疗的可能靶点的可能性。细胞疗法已成为一种潜在的替代方法,因为细胞可以提供肝脏功能并在肝实质中植入。已经提出了各种选择,包括人或其他物种的肝细胞、源自干细胞的肝细胞样细胞或更具未来感的替代物,例如与不同细胞类型、类器官和细胞-生物材料组合的联合疗法。在这篇综述中,我们旨在概述迄今为止开发的细胞疗法,重点介绍临床前和/或临床成就以及为了使它们在临床应用中完全有效和安全而需要克服的限制。本文是主题为“设计人类组织:即将进入你附近的实验室”的一部分。